Table 3.
1‐Year Follow‐Up
| Male (n = 984) | Female (n = 381) | P Value | |
|---|---|---|---|
| Reangiography (%) | 54.6 | 50.4 | 0.089 |
| CABG (%) | 6.3 | 3.0 | 0.155 |
| TVR (% of gender) | 7.5 | 4.2 | 0.196 |
| Rehabilitation (%) | 79.0 | 76.6 | 0.415 |
| Drug therapy (%) | |||
| β‐Blocker | 89.1 | 90.3 | 0.655 |
| ACE inhibitor | 77.4 | 68.8 | 0.075 |
| Statins | 85.9 | 80.5 | 0.036 |
| Antiplatelet therapy (%) | 0.617 | ||
| ASS or clopidogrel | 63.1 | 64.9 | |
| No ASS or clopidogrel | 5.7 | 6.6 | |
| ASS + clopidogrel | 31.2 | 28.5 |
Abbreviations: ACE, angiotensin‐converting enzyme; ASS, aspirin; CABG, coronary artery bypass grafting; TVR, target‐vessel revascularization. Fisher exact test is given for comparison between groups.
Percent values are separate for males and females.